akkermansia muciniphila

Cell therapyexperimental

Akkermansia muciniphila is a human intestinal symbiont, isolated from human feces. It is a mucin-degrading bacterium belonging to the genus Akkermansia, discovered in 2004 by Muriel Derrien and Willem de Vos at Wageningen University of the Netherlands. It belongs to the phylum Verrucomicrobiota and its type strain is MucT. It is under preliminary research for its potential beneficial associations with metabolic disorders. — Wikipedia

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2015 (NCT02637115)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2026

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • akkermansia muciniphila

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06992154Early Phase 1 (Phase 1)Mar 31, 2026Medical University of South Carolina, Pendulum Therapeutics
NCT05720299N/AMar 29, 2023Southern Medical University
NCT05417360N/AJul 22, 2022Maastricht University
NCT04797442Phase 2Jul 15, 2021Jiao Tong University
NCT04303481N/AAug 10, 2019TCI Co., Ltd.
NCT02637115N/ADec 1, 2015Université catholique de Louvain
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiao Tong UniversityAcademic/Hospital1112021
Maastricht UniversityAcademic/Hospital1112022
Medical University of South CarolinaAcademic/Hospital1112026
Pendulum TherapeuticsFor profit1012026
Southern Medical UniversityAcademic/Hospital1112023
TCI Co., Ltd.For profit1112019
Université catholique de LouvainAcademic/Hospital1112015
7 organizations
Page 1 / 1